SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Birkeland Kåre)
 

Sökning: WFRF:(Birkeland Kåre) > Heart failure and c...

  • Birkeland, Kåre I.Oslo Univ Hosp, Oslo, Norway.;Univ Oslo, Oslo, Norway (författare)

Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes : A large multinational cohort study

  • Artikel/kapitelEngelska2020

Förlag, utgivningsår, omfång ...

  • 2020-06-03
  • John Wiley & Sons,2020
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-423708
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-423708URI
  • https://doi.org/10.1111/dom.14074DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:143794371URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Aims To examine the manifestation of cardiovascular or renal disease (CVRD) in patients with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated with these diseases.Methods Patients free from CVRD were identified from healthcare records in England, Germany, Japan, the Netherlands, Norway and Sweden at a fixed date. CVRD manifestation was defined by first diagnosis of cardiorenal disease, or a stroke, myocardial infarction (MI) or peripheral artery disease (PAD) event. The mortality risk associated with single CVRD history of heart failure (HF), chronic kidney disease (CKD), MI, stroke or PAD was compared with that associated with CVRD-free status.Results Of 1 177 896 patients with T2D, 772 336 (66%) were CVRD-free and followed for a mean of 4.5 years. A total of 137 081 patients (18%) developed a first CVRD manifestation, represented by CKD (36%), HF (24%), stroke (16%), MI (14%) and PAD (10%). HF or CKD was associated with increased cardiovascular and all-cause mortality risk: hazard ratio (HR) 2.02 (95% confidence interval [CI] 1.75-2.33) and HR 2.05 (95% CI 1.82-2.32), respectively. HF and CKD were separately associated with significantly increased mortality risks, and the combination was associated with the highest cardiovascular and all-cause mortality risk: HRs 3.91 (95% CI 3.02-5.07) and 3.14 (95% CI 2.90-3.40), respectively.Conclusion In a large multinational study of >750 000 CVRD-free patients with T2D, HF and CKD were consistently the most frequent first cardiovascular disease manifestations and were also associated with increased mortality risks. These novel findings show these cardiorenal diseases to be important and serious complications requiring improved preventive strategies.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Bodegard, JohanAstraZeneca, Oslo, Norway (författare)
  • Eriksson, Jan W.Uppsala universitet,Klinisk diabetologi och metabolism(Swepub:uu)janer909 (författare)
  • Norhammar, AnnaKarolinska Institutet (författare)
  • Haller, HermannHannover Med Sch, Div Nephrol, Hannover, Germany (författare)
  • Linssen, Gerard C. M.Hosp Grp Twente, Dept Cardiol, Hengelo, Netherlands (författare)
  • Banerjee, AmitavaUCL, Inst Hlth Informat, London, England.;Univ Coll London Hosp, Dept Cardiol, London, England (författare)
  • Thuresson, MarcusStatisticon AB, Uppsala, Sweden (författare)
  • Okami, SuguruAstraZeneca, Osaka, Japan (författare)
  • Garal-Pantaler, ElenaTeam Gesundheit GmbH, Essen, Germany (författare)
  • Overbeek, JettyPHARMO Inst Drug Outcomes Res CRS, Utrecht, Netherlands (författare)
  • Mamza, Jil BillyAstraZeneca, Luton, Beds, England (författare)
  • Zhang, RuiqiAstraZeneca, Luton, Beds, England (författare)
  • Yajima, ToshitakaAstraZeneca, Osaka, Japan (författare)
  • Komuro, IsseiUniv Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan (författare)
  • Kadowaki, TakashiUniv Tokyo, Grad Sch Med, Dept Prevent Diabet & Lifestyle Related Dis, Tokyo, Japan.;Teikyo Univ, Mizonokuchi Hosp, Dept Metab & Nutr, Kawasaki, Kanagawa, Japan (författare)
  • Oslo Univ Hosp, Oslo, Norway.;Univ Oslo, Oslo, NorwayAstraZeneca, Oslo, Norway (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Diabetes, obesity and metabolism: John Wiley & Sons22:9, s. 1607-16181462-89021463-1326

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy